Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xiamen Amoytop Biotech CoSHSE:688278 +2.94%75 EV-to-FCF is 61.83 as of Jul. 27, 2026, which is 60% below its 10-year median of 152.87. GuruFocus rates SHSE:688278 with a GF Score™ of 75/100 and a GF Value™ of ¥106.91 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 343 Biotechnology companies, Xiamen Amoytop Biotech Co ranks worse than 82.22% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Xiamen Amoytop Biotech Co's Enterprise Value is ¥23,849 Mil.
Xiamen Amoytop Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥386 Mil. Therefore, Xiamen Amoytop Biotech Co's EV-to-FCF for today is 61.83.
The historical rank and industry rank for Xiamen Amoytop Biotech Co's EV-to-FCF or its related term are showing as below:
SHSE:688278'
s EV-to-FCF Range Over the Past 10 Years
Min: -1604.77 Med: 152.87 Max: 215841.27
Current: 61.83
During the past 10 years, the highest EV-to-FCF of Xiamen Amoytop Biotech Co was 215841.27. The lowest was -1604.77. And the median was 152.87.
SHSE:688278's EV-to-FCF is ranked worse than 82.22% of 343
companies
in the Biotechnology industry
Industry Median: 14.79
vs SHSE:688278: 61.83
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xiamen Amoytop Biotech Co (SHSE:688278) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xiamen Amoytop Biotech Co's PE Ratio (TTM) for today is calculated as:
Xiamen Amoytop Biotech Co's share price for today is ¥60.63.
Xiamen Amoytop Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Xiamen Amoytop Biotech Co EV-to-FCF Related Terms
Xiamen Amoytop Biotech Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688278 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Xiamen Amoytop Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xiamen Amoytop Biotech Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xiamen Amoytop Biotech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Xiamen Amoytop Biotech Co's EV-to-FCF falls into.
Xiamen Amoytop Biotech Co's current Enterprise Value is ¥23,849 Mil.
Xiamen Amoytop Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥386 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xiamen Amoytop Biotech Co (SHSE:688278) has a EV-to-FCF of 61.83 as of Jul. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xiamen Amoytop Biotech Co and its competitors. This is 60% below median its historical median of 152.87. According to the industry distribution chart, Xiamen Amoytop Biotech Co ranks #282 out of 343 companies in the Biotechnology industry, placing it in the top 82.2%.
Is Xiamen Amoytop Biotech Co's EV-to-FCF too high?
Xiamen Amoytop Biotech Co's current EV-to-FCF of 61.83 is 60% below median its 10-year median of 152.87. The Biotechnology industry median EV-to-FCF is 14.79. Xiamen Amoytop Biotech Co's value of 61.83 is 318.1% above this industry median. Based on the distribution chart, Xiamen Amoytop Biotech Co ranks #282 out of 343 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xiamen Amoytop Biotech Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xiamen Amoytop Biotech Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xiamen Amoytop Biotech Co ranks #282 out of 343 companies for EV-to-FCF. This places Xiamen Amoytop Biotech Co in the lower half of its industry. The industry median EV-to-FCF is 14.79. Xiamen Amoytop Biotech Co's value of 61.83 is 318.1% above this benchmark. While the company's 10-year median is 152.87 vs. the industry median of 14.79, Xiamen Amoytop Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.79, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xiamen Amoytop Biotech Co's current EV-to-FCF of 61.83 is 318.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xiamen Amoytop Biotech Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xiamen Amoytop Biotech Co's current EV-to-FCF is 61.83, which is 60% below median its own 10-year median of 152.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xiamen Amoytop Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co (SHSE:688278) is currently considered Possible Value Trap. The stock's GF Value™ is ¥106.91, compared to a current price of ¥60.63 — trading 43.3% below its estimated fair value. The current EV-to-FCF is 61.83, which is 60% below median its 10-year median of 152.87 and 318.1% above the Biotechnology industry median of 14.79. Xiamen Amoytop Biotech Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Xiamen Amoytop Biotech Co (SHSE:688278), the current EV-to-FCF is 61.83 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xiamen Amoytop Biotech Co (SHSE:688278) Overvalued in 2026?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co stock appears to be undervalued.
The current stock price of ¥60.63 is trading 43.3% below its estimated GF Value™ of ¥106.91.
GuruFocus considers Xiamen Amoytop Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688278:
EV-to-FCF: 61.83 (60% below median its 10-year median of 152.87)
GF Value™: ¥106.91 vs. price of ¥60.63 (43.3% below fair value)
Industry Position: 318.1% above the Biotechnology median (#282 of 343)
No single metric tells the full story. See the SHSE:688278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.
75GF Score
Get the complete analysis for SHSE:688278
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688278 has been successfully added to your 
